L8.1 Atherosclerosis and Lipid lowering drugs Flashcards
1
Q
What is dyslipidaemia and what are its indications
A
- dyslipidaemia = abnormal lipid profile
- Elevated cholesterol
- Elevated trigly
- Or both
- can lead to atherosclerosis, increased risk of MI, stroke
2
Q
What level of cholesterol is considered igh risk and what is the treatment target?
A
- high risk > 7.5 mmol/L total cholesterol,
- treatment target < 4 mmol/L
3
Q
Considerations for the treatment for dyslipidaemia?
A
- Consider cardiovascular status and risk factors
- Consider secondary causes
- obesity, diabetes, hypothyroidism
- Treat the secondary causes
- manage modifiable risk factors
- stop smoking - increase probability of stroke and infarct
- avoid alcohol - able to increase trigly levels
- weight reduction - increase exercise (able to restore lipid balance and improves CV health)
- modify diet
4
Q
Target for hypercholesterolaemia - Diet
A
- Reduce saturated and trans fats
- Introduce
- Mediterranean diet – reduces CV risk, not LDL cholesterol
- Plant sterol esters (from margarine) – reduce LDL cholesterol
- fish oils – reduce triglycerides, increase HDL cholesterol
- lifestyle/diet intervention for people at low risk (for those with CV risk, need therapeutic intervention)
5
Q
Sources of cholesterol
A
- cholesterol derived from:
- diet (in animal fat, eggs - absorbed via intestine)
- de novo synthesis (primarily in liver) (adequate)Acetyle Coa → 3-hydroxy-3-methylglutaryl-CoA (by HMG-CoA) (RATE LIMITING STEP) → mevalonic acid → cholesterol
- Too much cholesterol inhibits rate limiting step to limit amount of cholesterol syn

6
Q
Fate of cholesterol
A
- stored in liver for export in VLDL (very low density lipoproteins)
- converted to bile acids, stored in gall bladder to emulsify fat
- used for membrane synthesis
7
Q
How are cholesterol transported around?
A
- Trigly and cholesterol do not circulate freely
- transported in plasma lipoprotein
- – chylomicrons - from small intestine through lymph cells
- – Very low density lipoproteins (VLDL)
- – Intermediate density lipoproteins (IDL)
- – Low density lipoproteins (LDL = “bad” cholesterol)
- – High lipoproteins (HDL = “good” cholesterol) - takes bad cholesterol from bad deposits
8
Q
Transport and metabolism of Cholesterol
A
- In capillaries, fat, muscles have enz called lipoprotein liapose
- Trgiylcerides Hydrolysed into free fatty acids → Taken up by chylomicrons and vLDLs
- Chylomicrons takes free fatty acids to liver
- vLDL remnants:
- takes FFA into liver
- converted into LDL → laid down in extrahepatic tissues
- HDL takes deposit of cholestorol and brings it back to the liver

9
Q
Significance of the HDL/LDL ratio
A
- Normal cholesterol levels does not mean you have a healthy lipid profile - it’s the ratio of HDL/LDL that shows whether you have a good lipid prolife
10
Q
Statins
A
- HMG-CoA reducatase inhibitor (hypercholesterolaemia)
- Inhibit cholesterol synthesis
- decrease mevalonic acid (precursor for cholestorol) and therefore cholesterol synthesis
- compensatory increase in hepatic LDL receptors (take back cholesterol that is circulating)
- increased clearance of LDL (with bound cholesterol) from blood
- decreased plasma total cholesterol and LDL (and TGs to lesser extent)
- increased plasma HDL
11
Q
Uses of statin
A
- high LDL or high trigyl levels
- Needs to be used for number of years before seeing benefits but good at lowering cholesterol
- Poor compliance due to not perceiving any benefits from taking drug (not due to SE)
12
Q
Precaution with statins
A
- avoid grapefruit juice (common metabolic pathway increases toxicity of statins - the cP450 pathways)
- Higher levels of circulating statin leading to higher toxic effects
- drug-drug interactions also due to cP450 pathways
- statin levels are
- increased by some antibiotics, antifungals and fibrates
- decreased by phenytoin, barbiturates, glitazones (which treat diabetes)
13
Q
Monitoring of statin administration
A
- measure of liver function, monitor (by looking at serum aminotransferase) at 2-4 month intervals, reduce dose if necessary
- May have liver toxicity
- minor increases in creatine kinase
- can lead to muscle pain and tenderness
14
Q
Statin SE
A
- mild GI symptoms, headache, insomnia, dizziness
- rare but serious adverse effects
- – myopathy (minimised by UQ10 treatment)
- – rhabdomyolysis (breakdown of muscle resulting in myoglobin release into the bloodstream)
- – renal failure
- – hepatitis, liver failure
15
Q
Contra-indication of statins
A
- in pregnancy
- impaired fetal myelination
- contra-indication with AB - may elevate statin levels and leads to toxicity
- Withheld during infection/post-surgery/post-trauma
16
Q
Dosage of statin administered
A
- Starting does of statin is very variable
- Initial does causes the most significant effect in lowering LDL levels in the plasma
- Subsequent increase dose does not show significant increase in effect, but has significant increase adverse effects
17
Q
Bile acid sequestrants/resins
A
- (hypercholesterolaemia)
- Cholestyramine, colestipol
- Binds to bile acids in intestine, acid cannot be taken up and reused
- Increase demand for cholesterol for bile acid synthesis → upregulate hepatic LDL → increase removal of LDL and increased cholesterol metabolism
- oral route - granular preparations, taken with liquid
- non-absorbable macromolecules
18
Q
Resins SE
A
- mainly GIT where it works
- abdominal discomfort, bloating, constipation, flatulence
- rare adverse effects
- increased TGs, faecal impaction
- Need to drink a lot of water with these drugs
- decreases absorption of other drugs
- give other drugs hours before or after resin
19
Q
Ezetimibe
A
- (Hypercholesterolaemia)
- specifically inhibits cholesterol absorption in the intestine by binding to a sterol transporter
- does not affect absorption of bile acids, fat soluble vitamins
- lowers LDL
20
Q
Ezetimibe SE
A
- diarrhea, headache, tiredness
- allergic reactions, severe joint or stomach pain
- can be used alone in statin-intolerant patients, or in combination with all other lipid-lowering agents including statins (to reduce statin dose)
21
Q
Nicotinic acid/niacin
A
- (hypercholesterolaemia)
- Nicotinic acid = niacin = vitamin B3
- mechanism unclear - but shows less cholesterol circulating
- – decrease secretion of VLDL particles from liver
- – reduces plasma LDL and triglycerides (so also for mixed hyperlipidaemia)
- – increases HDL
- – lowers potentially atherogenic lipoprotein - formed from LDL found in plaques which inhibits thrombolysis
- By lowering, niacin inhibits thrombus formation
22
Q
Niacin SE
A
- common adverse effects
- – vasosodilation, flushing, hypotension
- – nausea, vomiting
- – tolerance develops to flushing as gastric upsets (positive effects of taking drugs still persists)
- rare adverse effects – itching
- – glucose intolerance
- – uric acid retention
- – may increase hepatic impairment
23
Q
Are niacins widely used?
A
- not widely used except in combination (drug of last resort)
24
Q
Fibrates
A
- (for hypertriglyceridaemia)
- Gemfibrozil, fenofibrate
- agonists at nuclear receptors, so regulate gene expression
- – peroxisome proliferator activated receptor a
- – increased synthesis of lipoprotein lipase (LPL)
- increase lipolysis of lipoprotein triglyceride
- moderate reduction in plasma triglycerides
- moderate increase in HDL
- variable effects on LDL (won’t use fibrates in patients with high cholesterol levels)
- generally used as adjunct to dietary changes for high TGs, mixed hyperipidaemia, and second line therapy for hypercholesterolaemia
25
Fibrate SE and precautions
* mild elevation of serum aminotransferase (may have liver toxicity)
* Need to monitor
* Common adverse effects
* – nausea, dry mouth, headache, rash
* Rare adverse effects – arrhythmias
* – gallstones
* – photosensitivity – impotence
* – depression
26
Fish oils
* (for hypretriglyceridaemia)
* Omega 3 fatty acids e.g. eicoapentanoic acid (EPA) docosahexanoic acid (DHA)
* reduce triglycerides and VLDL also increase HDL
* Plant sources contain a-linolenic acid (ALA) which can be converted to EPA/DHA,
* but conversion is variable (fatty fish is more reliable)
27
Possible side effects:
* aftertaste, fishy burps
* diarrhea, abdominal discomfort
* blood thinning effect
28
What is required for severe hypertriglyceridemia
* Severe hypertriglyceridemia requires polytherapy
* low fat diet, fibrates, fish oils, statins, niacin, orlistat (used for obesity inhibits fat absorption from gut)
29
Summary of the drugs
* Statin = first line therapy
* Still need to lower other crap, use other drugs

30
Summary of sites of drug action
* Dietary trigly abs in SI, packaged into chylomicrons
* Ezetimibde
* Bile acid resins
* Fibrates acting on lipoprotein lipase in capillaries
* Increase hydrolysis of triglycerides
* Increase release of FFA and taken up in adjacent tissues
* Statins
* Altering cholesterol syn within liver
* Reduction in the conversion (the RATE LIMITING STEP)
